0
0
A recent study published in JAMA Network Open has revealed that mindfulness-based group interventions can significantly reduce opioid cravings among adults with opioid use disorder (OUD) undergoing buprenorphine treatment. The study, led by Dr. Zev Schuman-Olivier and colleagues from Cambridge Health Alliance in Malden, Massachusetts, compared the efficacy of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) program with an active control group using a recovery support curriculum.
The M-ROCC program, a 24-week, trauma-informed, and mindfulness-based curriculum, was found to be effective in reducing opioid cravings compared to the traditional recovery support group. Participants in the M-ROCC group experienced a more substantial reduction in cravings, even though opioid, cocaine, and benzodiazepine use remained comparable across both groups. Additionally, anxiety levels were reduced in both groups, with no significant difference observed between the two.
The study included 196 participants who were randomly assigned to either the M-ROCC program or a recovery support control group, which utilized evidence-based approaches for treating substance use disorders without the incorporation of mindfulness techniques. Both groups received regular check-ins and interventions to support their recovery.
The results are promising, suggesting that mindfulness-based approaches may be particularly beneficial for individuals with OUD who continue to experience opioid cravings during their buprenorphine treatment.
“The study suggests that mindfulness-based groups may be particularly useful for reducing craving among patients with OUD who are experiencing residual opioid craving during buprenorphine treatment,” the authors noted.
While the study did not find significant differences in overall opioid or other drug use, the marked reduction in craving provides an encouraging avenue for enhancing treatment outcomes for individuals battling opioid dependence.
It is worth mentioning that one of the authors disclosed financial ties to Alkermes, a company involved in the development of treatments for opioid use disorder.
Disclaimer: This article is based on a recent study and should not be considered medical advice. For personalized treatment options, please consult a healthcare professional.
